Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2017

  • ID: 4435222
  • Report
  • 183 pages
  • P&S Market Research
1 of 3
IPF pipeline in 2017

The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.

Insights on Pipeline Segments:

As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor. The analysis was also done based on route of administration and it was found that major drug candidates are being developed to be administered by oral route.

More than 10 drug candidates received Orphan Drug Designation (ODD)

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.

IPF Pipeline Analysis:
  • By route of administration
  • By molecule type
  • By company
  • By phase
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Molecule Type
1.3.3. Pipeline Analysis by Route of Administration
1.4. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By industry participants
2.2.1.2. By company type

3. Executive Summary

4. Pipeline Outlook
4.1. IPF Disease Overview
4.1.1. Signs and Symptoms
4.1.2. PAThophysiology
4.1.3. Diagnosis
4.1.4. Treatment
4.1.5. Epidemiology
4.2. Key Drivers
4.3. Key Barriers
4.4. IdioPAThic Pulmonary Fibrosis Pipeline Analysis
4.4.1. Pipeline Analysis by Phase
4.4.2. Pipeline Analysis by Molecule Type
4.4.3. Pipeline Analysis by Route of Administration
4.4.4. Pipeline Analysis by Company
4.5. Inactive Drug Candidates
4.6. Discontinued Drug Candidates

5. IPF Therapeutics Pipeline Analysis by Phase (2017)
5.1. Phase III: Drug Profiles
5.1.1. Phase III Drugs
5.1.1.1. Pre-Clinical Studies
5.1.1.2. Clinical Trials
5.1.1.3. Clinical Trial Results
5.1.1.4. Strategic Developments
5.1.1.5. Financing
5.1.1.6. Designations
5.1.1.7. Grants
5.1.1.8. Patents
5.1.1.9. Technology
5.2. Phase II: Drug Profiles
5.2.1. Phase II Drugs
5.2.1.1. Pre-Clinical Studies
5.2.1.2. Clinical Trials
5.2.1.3. Clinical Results
5.2.1.4. Strategic Developments
5.2.1.5. Financing
5.2.1.6. Designations
5.2.1.7. Grants
5.2.1.8. Patents
5.2.1.9. Technology
5.3. Phase I: Drug Profiles
5.3.1. Phase I Drugs
5.3.1.1. Pre-Clinical Studies
5.3.1.2. Clinical Trials
5.3.1.3. Strategic Developments
5.3.1.4. Financing
5.3.1.5. Grants
5.3.1.6. Patents
5.3.1.7. Technology
5.4. Pre-Clinical: Drug Profiles
5.4.1. Pre-Clinical Studies
5.4.2. Strategic Developments
5.4.3. Financing
5.4.4. Grants
5.4.5. Patents
5.4.6. Technology
5.5. Discovery: Drug Profiles
5.5.1. Strategic Developments
5.5.2. Financing
5.5.3. Grants
5.5.4. Patents
5.5.5. Technology

6. Clinical Trials Analysis
6.1. Clinical Trials Analysis, by Region
6.2. Clinical Trials Analysis, by Trial Status

7. Competitive Landscape
7.1. Key Players Benchmarking for IPF Therapeutics Pipeline
7.2. SWOT Analysis of IPF Therapeutics Pipeline
7.2.1. Strengths
7.2.2. Weaknesses
7.2.3. Opportunities
7.2.4. Threats

8. Company Profiles
8.1. Companies having Pipeline of IPF Therapeutics
8.1.1. Business Overview
8.1.2. Product and Service Offerings

9. Appendix
9.1. Abbreviations
9.2. Related Reports

Note: Certain sections of the above table of contents would vary according to the availability of information.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll